Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $3.8650 (0.78%) ($3.8650 - $3.8650) on Wed. Jun. 15, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.17% (three month average) | RSI | 41 | Latest Price | $3.8650(0.78%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -5.1% a day on average for past five trading days. | Weekly Trend | TGTX declines -4.9% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(75%) ARKG(71%) IBB(65%) ARKK(64%) IBUY(55%) | Factors Impacting TGTX price | TGTX will decline at least -3.585% in a week (0% probabilities). VXX(-63%) VIXM(-52%) TBT(-26%) UUP(-19%) USO(-12%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.585% (StdDev 7.17%) | Hourly BBV | -0.5 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-22.91(-692.76%) | Resistance Level | $4.68 | 5 Day Moving Average | $4.25(-9.06%) | 10 Day Moving Average | $4.29(-9.91%) | 20 Day Moving Average | $4.68(-17.41%) | To recent high | -63.3% | To recent low | 0.8% | Market Cap | $489m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |